Mesoblast (MEOBF) Change in Receivables (2014 - 2024)
Mesoblast's (MEOBF) quarterly Change in Receivables came in at -$15.5 million in Q2 2024, down 13006.78% year-over-year from N/an in Q3 2023, and down 13006.78% quarter-over-quarter from -$118000.0 in Q2 2023.
Powered by 
Analysis
Mesoblast (MEOBF) Change in Receivables (2014 - 2024) Analysis & Trends
Mesoblast has disclosed Change in Receivables across 11 years of filings, most recently posting -$15.5 million for Q2 2024.
- In Q2 2024, Change in Receivables fell 13006.78% year-over-year to -$15.5 million; the TTM figure through Jun 2024 stood at -$16.8 million (down 1876.17% YoY), while the FY2026 annual figure was -$42.8 million, down 952.94% from the prior year.
- Change in Receivables came in at -$15.5 million for Q2 2024 at Mesoblast, down from -$118000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $1.2 million in Q2 2022 to a low of -$15.5 million in Q2 2024.
- Average Change in Receivables over 5 years is -$1.3 million, with a median of -$426500.0 recorded in 2021.
- Year-over-year, Change in Receivables jumped 387.41% in 2022 and sank 13006.78% in 2024.
- Over 5 years, Change in Receivables stood at -$858000.0 in 2020, then surged by 50.58% to -$424000.0 in 2021, then slumped by 197.64% to -$1.3 million in 2022, then surged by 90.65% to -$118000.0 in 2023, then slumped by 13006.78% to -$15.5 million in 2024.
- Per Business Quant data, the three most recent Change in Receivables figures were -$15.5 million in Q2 2024, -$118000.0 in Q2 2023, and $9000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 11.97 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 20.36 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 1.60 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 45.46 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -17.99 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 3.33 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -15.47 Mn |
| Jun 30, 2023 | -118,000.00 |
| Mar 31, 2023 | 9,000.00 |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | 519,000.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | -424,000.00 |
| Sep 30, 2021 | -1.08 Mn |
| Jun 30, 2021 | -429,000.00 |
| Mar 31, 2021 | 417,000.00 |
| Dec 31, 2020 | -858,000.00 |
| Sep 30, 2020 | -869,000.00 |
| Mar 31, 2020 | -556,000.00 |
| Dec 31, 2019 | -620,000.00 |
| Sep 30, 2019 | -15.38 Mn |
| Mar 31, 2019 | 358,000.00 |
| Dec 31, 2018 | 20.56 Mn |
| Sep 30, 2018 | -19.62 Mn |
| Jun 30, 2018 | 597,000.00 |